Abstract:The adenosine monophosphate activated protein kinase (AMPK) is critical in the regulation of important cellular functions such as lipid, glucose, and protein metabolism; mitochondrial biogenesis and autophagy; and cellular growth. In many diseases—such as metabolic syndrome, obesity, diabetes, and also cancer—activation of AMPK is beneficial. Therefore, there is growing interest in AMPK activators that act either by direct action on the enzyme itself or by indirect activation of upstream regulators. Many natural compounds have been described that activate AMPK indirectly. These compounds are usually contained in mixtures with a variety of structurally different other compounds, which in turn can also alter the activity of AMPK via one or more pathways. For these compounds, experiments are complicated, since the required pure substances are often not yet isolated and/or therefore not sufficiently available. Therefore, our goal was to develop a screening tool that could handle the profound heterogeneity in activation pathways of the AMPK. Since machine learning algorithms can model complex (unknown) relationships and patterns, some of these methods (random forest, support vector machines, stochastic gradient boosting, logistic regression, and deep neural network) were applied and validated using a database, comprising of 904 activating and 799 neutral or inhibiting compounds identified by extensive PubMed literature search and PubChem Bioassay database. All models showed unexpectedly high classification accuracy in training, but more importantly in predicting the unseen test data. These models are therefore suitable tools for rapid in silico screening of established substances or multicomponent mixtures and can be used to identify compounds of interest for further testing.

Drug Design for AMP-Activated Protein Kinase Agonists in Silico

Study of Amp-Activated Protein Kinase Agonists by Structure-Based Drug Designing

Computational screening and QSAR analysis for design of AMP-activated protein kinase agonist

Computer-aided drug design for AMP-activated protein kinase activators.

In Silico Design for Adenosine Monophosphate-Activated Protein Kinase Agonist from Traditional Chinese Medicine for Treatment of Metabolic Syndromes.

Targeting of AMP-activated protein kinase: prospects for computer-aided drug design

Modeling Structure–Activity Relationship of AMPK Activation

Discovery of natural adenosine monophosphate‐activated protein kinase activators through virtual screening and activity verification studies

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Synthesis, anticancer evaluation and in silico studies of novel N‐substituted arylidenethiazolidine‐2,4‐dione derivatives as adenosine monophosphate‐activated protein kinase activators

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Furthering the Design and the Discovery of Small Molecule ATP-competitive Mtor Inhibitors As an Effective Cancer Treatment

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

Structure-function analysis of the AMPK activator SC4 and identification of a potent pan AMPK activator

Structural and Biochemical Insights into the Allosteric Activation Mechanism of AMP‐activated Protein Kinase

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Structural Insight into the Autoinhibition Mechanism of AMP-activated Protein Kinase

AMP-activated protein kinase: the current landscape for drug development

In silico hit optimization toward AKT inhibition: fragment-based approach, molecular docking and molecular dynamics study